Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Preamendment Class III device classification

This article was originally published in The Gray Sheet

Executive Summary

Preamendment Class III device classification: FDA has received data from approximately 10% of manufacturers required to submit safety and effectiveness information by the Aug. 14 deadline under the agency's August 1995 call for data on pre-1976 Class III devices per section 515(i) of the FD&C Act ("The Gray Sheet" Aug. 21, 1995, p. 6). The data, for preamendment devices for which FDA has not yet issued a call for PMAs, will be used by the agency to determine which devices will remain in Class III and which can be downclassified. FDA's Office of Device Evaluation sent a letter the week of July 29 to 98 firms registered as manufacturers of the 17 devices covered by the Aug. 14 deadline, reminding them of the impending due date. For further information, contact ODE's Melpi Jeffries at 301/594-2186...

You may also be interested in...



Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel